Filing Details
- Accession Number:
- 0001179110-21-008140
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-08-12 10:00:22
- Reporting Period:
- 2021-08-10
- Accepted Time:
- 2021-08-12 10:00:22
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 744218 | Celldex Therapeutics Inc. | CLDX | In Vitro & In Vivo Diagnostic Substances (2835) | 133191702 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1709024 | Bates Samuel Martin | C/O Celldex Therapeutics, Inc. 53 Frontage Road Hampton NJ 08827 | Svp And Cfo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-08-10 | 10,302 | $9.02 | 21,037 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-08-10 | 2,056 | $45.25 | 18,981 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-08-10 | 11,079 | $2.78 | 30,060 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-08-10 | 682 | $45.25 | 29,378 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Incentive Stock Option | Disposition | 2021-08-10 | 10,302 | $0.00 | 10,302 | $9.02 |
| Common Stock | Incentive Stock Option | Disposition | 2021-08-10 | 11,079 | $0.00 | 11,079 | $2.78 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 16,030 | 2028-06-13 | No | 4 | M | Direct | |
| 31,921 | 2029-06-19 | No | 4 | M | Direct |
Footnotes
- On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
- This option was previously reported as covering 395,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.
- Represents shares sold upon exercise of option in payment of exercise price pursuant to broker-assisted cashless exercise transaction.
- 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
- 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
Billionaire Hedge Funds
